Abstract B143: HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models

伊立替康 喜树碱 可药性 医学 药理学 药效学 癌症研究 拓扑异构酶 合成致死 癌症 结直肠癌 药代动力学 DNA修复 生物 内科学 体外 遗传学 基因 生物化学
作者
Stéphane Ferretti,Isabel Jaco,Eric A. Decker,Christelle Hemmerlin,Clemens Scheufler,Cornelia Quadt,Dario Sterker,Elena Gavioli,Eloísa Jiménez Núñez,Ernesta Dammassa,Fanny Schaeffer,Geneviève Albrecht,Giorgia Clementi,Hans‐Joerg Martus,Jacques Hamon,J. Hinrichs,Laurent Laborde,Marion Dourdoigne,Michele Moschetta,Ramona Stump
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:22 (12_Supplement): B143-B143 被引量:1
标识
DOI:10.1158/1535-7163.targ-23-b143
摘要

Abstract Colorectal carcinoma (CRC) as well as other indications that have lost competence in mismatch repair and have a phenotype known as microsatellite instability (MSI), remain a significant unmet medical need. Large-scale functional genomics screens across cell line panels have identified the Werner Syndrome RecQ helicase (WRN) as being synthetic lethal with MSIhigh cancers. Thus, WRN inhibitors may offer a new therapeutic avenue in MSIhigh cancers. We report the preclinical characteristics of HRO761, a first-in-class, highly potent and selective inhibitor of WRN helicase, with optimized drug-like properties. We evaluated the pharmacokinetics and pharmacodynamics of HRO761 when administered orally once daily in MSIhigh and also assessed the efficacy as single agent across cell (CDX) and patient-derived (PDX) xenografts as well as in combination with irinotecan, a prodrug derivative of camptothecin which acts as topoisomerase I inhibitor. Daily oral administration of HRO761 was highly efficacious across the CDX and PDX models evaluated with a disease control rate of 70% across all indications. In the SW48 CDX model, tumor regression was sustained for 2 months at the highest dose followed by slow relapse. HRO761 also induced WRN degradation, activated the DNA damage response and induced p53 target genes in a dose dependent manner. In vitro combination with irinotecan deepened sensitivity to HRO761 with a more sustained response in MSIhigh CRC cell lines. Combining administration of HRO761 daily with irinotecan weekly was highly efficacious and beneficial over single agent in CDX and PDX models. In CDX models, the combination showed a robust benefit, translating into homogeneous, sustained regression leading to a dose-dependent tumor growth delay even after treatment discontinuation. Overall, we demonstrate that the novel, selective, first-in-class WRN inhibitor HRO761 is a promising therapeutic approach for the treatment of MSIhigh cancer patients either as single agent or in combination with irinotecan. Clinical development is currently ongoing to assess the safety, tolerability and preliminary anti-tumor activity in patients with MSIhigh colorectal cancer and other MSIhigh solid tumors [clinicaltrials.gov NCT05838768]. Citation Format: Stephane Ferretti, Isabel Jaco, Andrea Decker, Christelle Hemmerlin, Clemens Scheufler, Cornelia Quadt, Dario Sterker, Elena Gavioli, Eloisa Jimenez Nunez, Ernesta Dammassa, Fanny Schaeffer, Genevieve Albrecht, Giorgia Clementi, Hansjoerg Martus, Jacques Hamon, Juergen Hinrichs, Laurent Laborde, Marion Dourdoigne, Michele Moschetta, Ramona Stump, Rita Andraos-Rey, Sarah Welly, Stephanie Barbe, Vincent Romanet, Markus Reschke, Ruben De Kanter, Michael Jensen, Henrik Moebitz, Marta Cortes Cros. HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr B143.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
西西完成签到,获得积分10
刚刚
ymshi完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
1秒前
2秒前
pudding完成签到,获得积分10
2秒前
充电宝的应助被米米采纳,获得10
2秒前
3秒前
邻家小胖完成签到,获得积分10
4秒前
科研通AI6.4的应助被轻松书竹采纳,获得10
4秒前
Arabella完成签到,获得积分10
4秒前
爆米花的应助被lcx采纳,获得10
4秒前
许路发布了新的文献求助10
4秒前
小也完成签到,获得积分10
5秒前
英俊依丝完成签到,获得积分10
5秒前
5秒前
邢丽妍完成签到,获得积分10
6秒前
WHL发布了新的文献求助10
6秒前
能干秋珊发布了新的文献求助10
6秒前
十月完成签到,获得积分10
6秒前
源涧菡完成签到,获得积分10
6秒前
君无戏言发布了新的文献求助10
6秒前
6秒前
喂鱼完成签到,获得积分10
6秒前
WYH发布了新的文献求助10
6秒前
淡然柚子完成签到,获得积分10
6秒前
雨过天晴完成签到,获得积分10
7秒前
YPHCC发布了新的文献求助10
7秒前
苹果绝悟完成签到 ,获得积分10
7秒前
7秒前
xyr完成签到 ,获得积分10
8秒前
8秒前
young完成签到 ,获得积分10
8秒前
鸭梨完成签到,获得积分10
8秒前
byloo完成签到,获得积分10
8秒前
爆米花的应助被wumin26采纳,获得10
8秒前
lucky完成签到 ,获得积分10
8秒前
有点儿小库完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162